Want to see ELMD full AI Analyst Report?
ELMD Stock Chart & Stats
$38.41
$1.38(3.59%)
At close: 4:00 PM EDT
$38.41
$1.38(3.59%)
Day’s Range― - ―
52-Week Range$18.81 - $47.40
Previous CloseN/A
Volume19.90K
Average Volume (3M)116.30K
Market Cap
$350.99M
Enterprise Value$185.46
Total Cash (Recent Filing)$16.98M
Total Debt (Recent Filing)$81.00K
Price to Earnings (P/E)34.8
Beta0.81
Next Earnings
Aug 25, 2026EPS Estimate
0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.22
Shares Outstanding8,280,064
10 Day Avg. Volume115,935
30 Day Avg. Volume116,302
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)4.24
Price to Sales (P/S)2.86
P/FCF Ratio16.53
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.48
Revenue Forecast (FY)$83.60M
Bulls Say, Bears Say
Bulls Say
Margin SustainabilityElectromed’s device and consumables model delivers very high gross margins (~78% TTM) and a step-up in net margin to ~14% TTM. This margin profile and recent operating-leverage gains are durable advantages that support reinvestment, profitability resilience and cash generation over multiple quarters.
Balance Sheet StrengthA conservative, debt-free balance sheet with meaningful cash and working capital gives Electromed strategic flexibility. It supports investments in commercial scale, MFG optimization, and share repurchases while insulating the business from reimbursement timing shocks and reducing refinancing risk over the medium term.
Direct Sales ProductivityThe direct sales model shows high rep productivity (>$1.16M annualized per rep) and sustained top-line momentum (14 straight YoY growth quarters). Efficient field economics make incremental headcount a scalable lever, indicating a durable go-to-market that can compound revenue as coverage expands.
Bears Say
Growth Reliance On Sales HiringManagement’s growth plan depends materially on adding and ramping field reps, which introduces execution risk. Multi-month ramp times delay returns on hiring, raise near-term sales productivity variance, and mean sustained growth requires consistent hiring success and quality recruiting over time.
Channel ConcentrationRevenue remains heavily concentrated in direct home care, leaving Electromed exposed to payer or competitive shifts in that channel. Modest scale in hospitals/distributors limits resilience and optionality; durable growth depends on executing diversification without eroding home-care economics.
Guideline & Payer UncertaintyLong-term adoption of HFCWO therapy is tied to payer coverage and formal clinical guidelines. Uncertainty around guideline publication and variable conversion from clinician outreach can materially affect prescription rates and reimbursement consistency, constraining durable demand expansion.
Electromed News
ELMD FAQ
What was Electromed’s price range in the past 12 months?
Electromed lowest stock price was $18.80 and its highest was $47.40 in the past 12 months.
What is Electromed’s market cap?
Electromed’s market cap is $350.99M.
When is Electromed’s upcoming earnings report date?
Electromed’s upcoming earnings report date is Aug 25, 2026 which is in 12 days.
How were Electromed’s earnings last quarter?
Electromed released its earnings results on May 12, 2026. The company reported $0.35 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.1.
Is Electromed overvalued?
According to Wall Street analysts Electromed’s price is currently Overvalued.
Does Electromed pay dividends?
Electromed does not currently pay dividends.
What is Electromed’s EPS estimate?
Electromed’s EPS estimate is 0.32.
How many shares outstanding does Electromed have?
Electromed has 8,280,064 shares outstanding.
What happened to Electromed’s price movement after its last earnings report?
Electromed reported an EPS of $0.35 in its last earnings report, beating expectations of $0.25. Following the earnings report the stock price went up 25.11%.
Which hedge fund is a major shareholder of Electromed?
Currently, no hedge funds are holding shares in ELMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Electromed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
ELMD Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $2.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
106.06%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
13.39%
Trailing 12-Months
Company Description
Electromed
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy, muscular dystrophies, amyotrophic lateral sclerosis, and post-surgical complications; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.
ELMD Company Deck
ELMD Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights strong, broad-based financial performance (double-digit revenue growth, high operating leverage, margin durability), improved operational capability (completed manufacturing optimization, ePrescribe adoption), a healthy balance sheet (cash, no debt) and a large addressable bronchiectasis market supported by active clinical and digital outreach. Challenges include modest non-core revenue, reliance on ramping sales rep headcount for incremental growth, slowed share repurchases due to macro uncertainty, and remaining uncertainty on guideline publication and conversion rates from clinician engagement. Overall, the positives (robust revenue and profit expansion, operational wins, market opportunity) substantially outweigh the negatives.View all ELMD earnings summariesTechnical Analysis
Ownership Overview
7.17% Insiders
10.32% Mutual Funds
7.52% Other Institutional Investors
65.31% Public Companies and
Individual Investors